Page 14 - Pharmascience Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs 12-Apr-2021 [2021] Saline Laxatives Market is Expected to Surge with 5.0% CAGR With US$ 613.3 Million by 2027 – Coherent Market Insights SEATTLE, April 12, 2021, (PHARMIWEB) — The global saline laxatives market, by Age Group (Pediatric and Adult), By Route of Administration (Oral and Rectal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), accounted for US$ 396.3 million in 2019, and is projected to w...

Canadian Patent No. 2,461,202 (the  202 Patent), which was asserted by Bristol-Myers Squibb Canada Co. and Bristol-Myers Squibb Holdings Ireland Unlimited Company (collectively,  BMS). The 202 Patent claims the active ingredient apixaban and its use for the treatment and prevention of thromboembolic disorders (blood clots). Canadian Patent No. 2,791,171 (the  171 Patent), which was asserted by BMS and Pfizer Inc. (collectively,  BMS & Pfizer). The 171 Patent claims tablet formulations of apixaban. The Defendants' only non-infringement allegation was that the asserted claims of each of the...

Canmar 5 was a trend for a day or here to stay. This year, the Federal Court has seen increased attempts by litigants to resolve matters more expeditiously by way of dispositive motions. Summary judgment was granted in three cases 6 and two motions for default judgment were brought but dismissed based on insufficient evidence. ViiV Healthcare Company v. Gilead Sciences Canada, 8 the Court held that completion of discoveries is not a precondition to summary trial such that resolution may be sought at very early stages of the proceeding. We saw the Federal Court grant summary disposition to ...

Investegate announcements from Montreal Heart Institute, Colchicine reduces the risk of COVID-19-related complications

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Colchicine reduces the risk of COVID-19-related complications Montreal Heart InstituteJanuary 23, 2021 GMT MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the g...